Journal of Medicinal Chemistry · 2003 · 182 citations · 8 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryMolecular PharmacologyNeuropharmacologyAllosteric Drug DesignAllosteric ModulationAllosteric Modulator DesignGlutamatergic PharmacologyGlutamatergic SignalingReceptor PharmacologyAgonist ActivityAllosteric Receptor PharmacologyFear-potentiated StartleGlutamate AntagonistsGlutamate Receptor AntagonismMetabotropic ReceptorsPharmacology Of Glutamate ReceptorsSubtype Discovery
This report describes recently discovered novel allosteric modulators of metabotropic glutamate2 (mGlu2) receptors. These pyridylmethylsulfonamides (e.g., 3) potentiate glutamate, shifting agonist potency by 2-fold. This effect was specific for mGlu2 (vs mGlu1,3-8 receptors). Also, 3 failed to potentiate a chimeric mGlu2/1 receptor, demonstrating the mGlu2 transmembrane region's critical involvement. In a fear-potentiated startle model, 3 showed anxiolytic activity that was prevented by mGlu2/3 antagonist pretreatment. Thus, these pyridylmethylsulfonamides represent the first mGlu2 receptor potentiators discovered.
8
Stephan Urwyler, Johannes Mosbacher, Kurt Lingenhoehl et al. · PubMed · 2001 · 239 citations
Frédéric Knoflach, Vincent Mutel, Synèse Jolidon et al. · Proceedings of the National Academy of Sciences · 2001 · 236 citations · Full text
Medicine, Neuroscience, Pharmacology +17
Stephan Urwyler, Johannes Mosbacher, Kurt Lingenhoehl et al. · Molecular Pharmacology · 2001 · 218 citations
Medicine, Neuroscience, Pharmacology +17
Giuseppe Battaglia, James A. Monn, Darryle D. Schoepp · Neuroscience Letters · 1997 · 163 citations